Belite Bio Analyst Ratings
Belite Bio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 51.05% | HC Wainwright & Co. | $55 → $59 | Maintains | Buy |
| 08/10/2023 | 40.81% | HC Wainwright & Co. | → $55 | Reiterates | Buy → Buy |
| 07/28/2023 | 10.09% | Cantor Fitzgerald | → $43 | Initiates Coverage On | → Overweight |
| 07/26/2023 | -36% | SVB Leerink | → $25 | Initiates Coverage On | → Outperform |
| 07/25/2023 | 45.93% | Benchmark | → $57 | Reiterates | Buy → Buy |
| 07/25/2023 | 40.81% | HC Wainwright & Co. | → $55 | Reiterates | Buy → Buy |
| 06/20/2023 | 45.93% | Benchmark | → $57 | Reiterates | Buy → Buy |
| 06/05/2023 | 40.81% | HC Wainwright & Co. | $58 → $55 | Reiterates | → Buy |
| 04/04/2023 | 45.93% | Benchmark | → $57 | Reiterates | → Buy |
| 04/04/2023 | 48.49% | HC Wainwright & Co. | → $58 | Reiterates | → Buy |
| 02/22/2023 | 48.49% | HC Wainwright & Co. | → $58 | Reiterates | → Buy |
| 02/21/2023 | 48.49% | HC Wainwright & Co. | → $58 | Reiterates | → Buy |
| 08/01/2022 | 48.49% | HC Wainwright & Co. | → $58 | Initiates Coverage On | → Buy |
| 07/01/2022 | 45.93% | Benchmark | → $57 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/06/2023 | 51.05% | HC Wainwright & Co. | 55 美元 → 59 美元 | 維護 | 買 |
| 08/10/2023 | 40.81% | HC Wainwright & Co. | → 55 美元 | 重申 | 購買 → 購買 |
| 07/28/2023 | 10.09% | 坎託·菲茨傑拉德 | → 43 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 07/26/2023 | -36% | SVB Leerink | → 25 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 07/25/2023 | 45.93% | 基準 | → 57 美元 | 重申 | 購買 → 購買 |
| 07/25/2023 | 40.81% | HC Wainwright & Co. | → 55 美元 | 重申 | 購買 → 購買 |
| 06/20/2023 | 45.93% | 基準 | → 57 美元 | 重申 | 購買 → 購買 |
| 06/05/2023 | 40.81% | HC Wainwright & Co. | 58 美元 → 55 美元 | 重申 | → 購買 |
| 04/04/2023 | 45.93% | 基準 | → 57 美元 | 重申 | → 購買 |
| 04/04/2023 | 48.49% | HC Wainwright & Co. | → 58 美元 | 重申 | → 購買 |
| 02/22/2023 | 48.49% | HC Wainwright & Co. | → 58 美元 | 重申 | → 購買 |
| 02/21/2023 | 48.49% | HC Wainwright & Co. | → 58 美元 | 重申 | → 購買 |
| 08/01/2022 | 48.49% | HC Wainwright & Co. | → 58 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2022 年 1 月 7 日 | 45.93% | 基準 | → 57 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Belite Bio (BLTE)?
Belite Bio（BLTE）的目標價格是多少？
The latest price target for Belite Bio (NASDAQ: BLTE) was reported by HC Wainwright & Co. on November 6, 2023. The analyst firm set a price target for $59.00 expecting BLTE to rise to within 12 months (a possible 51.05% upside). 12 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月6日公佈了Belite Bio（納斯達克股票代碼：BLTE）的最新目標股價。該分析公司將目標股價定爲59.00美元，預計BLTE將在12個月內升至12個月內（可能上漲51.05％）。去年有12家分析公司公佈了評級。
What is the most recent analyst rating for Belite Bio (BLTE)?
分析師對Belite Bio（BLTE）的最新評級是多少？
The latest analyst rating for Belite Bio (NASDAQ: BLTE) was provided by HC Wainwright & Co., and Belite Bio maintained their buy rating.
HC Wainwright & Co. 對Belite Bio（納斯達克股票代碼：BLTE）的最新分析師評級由HC Wainwright & Co. 提供，Belite Bio維持買入評級。
When is the next analyst rating going to be posted or updated for Belite Bio (BLTE)?
Belite Bio（BLTE）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Belite Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Belite Bio was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Belite Bio的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Belite Bio的最新評級是在2023年11月6日發佈的，因此您應該預計下一個評級將在2024年11月6日左右公佈。
Is the Analyst Rating Belite Bio (BLTE) correct?
分析師評級 Belite Bio (BLTE) 正確嗎？
While ratings are subjective and will change, the latest Belite Bio (BLTE) rating was a maintained with a price target of $55.00 to $59.00. The current price Belite Bio (BLTE) is trading at is $39.06, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Belite Bio（BLTE）評級保持不變，目標股價爲55.00美元至59.00美元。Belite Bio（BLTE）目前的交易價格爲39.06美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。